Please assess the completion status of the following clinical trial:

Trial Title: Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Dated and signed written informed consent~* Male or female patients between 18 years and 75 years; patients \> 75 years if their karnofsky performance status is ≥ 80.~* Histologically proven squamous cell carcinoma or adenocarcinoma of the esophagus which is not curatively resectable. Resectability has to be defined by a surgeon before radiochemotherapy. The tumor is considered unresectable due to T-stage, N-stage, performance status, nutritional status, co-morbidity (pulmonal function, other), tumor location upper third or other reasons~* Karnofsky Performance Status ≥ 70~* Women of child-bearing potential must have a negative pregnancy test~* Adequate cardial-, pulmonal- and ear function~Adequate bone marrow function:~* leukocytes ≥ 3.0 x 10\^9/L~* neutrophiles ≥ 1.5 x 10\^9/L~* thrombocytes ≥ 100 x 10\^9/L~* hemoglobin ≥ 10.0 g/dl~Adequate liver function:~* bilirubin ≤ 2.0 mg/dl~* transaminases (serum glutamic pyruvic transaminase (SGPT), serum glutamic oxaloacetic transaminase (SGOT), gamma-GT) ≤ 3 x upper limit of normal (ULN)~Adequate kidney function:~* serum creatinine ≤ 1.5 mg/dl~* creatinine clearance ≥ 50 ml/min according to Cockcroft-Gault Formula~* no known allergies against chimeric antibodies~* effective contraception for male and female patients if there is a risk of conception~Exclusion Criteria:~* distant metastasis~* previous treatment of esophageal cancer~* previous therapy with monoclonal antibodies and / or EGFR-targeted therapy~* previous second malignancies with exception of a history of a previous curatively treated basal cell carcinoma of the skin or pre-invasive cervix carcinoma~* serious concomitant disease or medical condition~* lung function: forced expiratory volume in one second (FEV1)) \< 1.1~* clinically relevant coronary artery diseases or known myocardial infarction within the last 12 months or ventricular ejection fraction (LVEF) below normal~* every active dermatological condition \> grade 1~* contraindications to receive cisplatin, 5-FU or cetuximab~* concurrent treatment with other experimental drugs or participation in another clinical trial within 30 days before study start~* patient pregnant or breast feeding~* known drug abuse, medication abuse, alcohol abuse~* social situations limiting the compliance with the study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab, Cisplatin, 5-FU, Radiotherapy (Type: EXPERIMENTAL): Cetuximab: Initial doses 400mg/m2 (day 1), followed by weekly doses of 250mg/m2 for 14 weeks in total, IV~5-fluorouracil (5-FU): 1000mg/m2 per day as continuous infusion on day 8-11 and 36-39, 750mg/m2/day as continuous infusion on day 71-74 and 99-102~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle (day 8-11, 36-39, 71-74 and 99-102)~radiotherapy: 59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery.
- Cisplatin, 5-FU, Radiotherapy (Type: ACTIVE_COMPARATOR): 5-FU: 1000mg/m2 per day as continuous infusion on day 1-4 and 29-32, 750mg/m2/day as continuous infusion on day 64-67 and 92-95~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle (day 1-4, 29-32, 64-67 and 92-95)~radiotherapy: 59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).